BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Wednesday, April 17, 2024
Home
»
Newsletters
» BioWorld
BioWorld
June 22, 2006
View Archived Issues
Celera Could Get $365M For Selling Cathepsin S Program
Completing its planned exit from small-molecule development, Celera Genomics sold its cathepsin S inhibitor program to Schering AG in a deal worth up to $365 million. (BioWorld Today)
Read More
Auxilium's Enzyme For Scar Tissue Effective In Phase III
Read More
New Research Shows Way To Save Neuron, Its Coat
Read More
Cell Therapeutics Gets Access To $72M Over Next Two Years
Read More
Other News To Note
Read More
Appointments And Advancements
Read More
Clinic Roundup
Read More